Free Newsletter
AstraZeneca launches $790M in Euro bonds
AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. and trade on the London exchange. The proceeds will cancel U.S. commercial paper the drugmaker took on to finance its buyout of the big biotech firm.
You'll recall that last fall AstraZeneca loosed a whopping $6.9 billion in bonds on the market, also to be used to pay off the MedImmune deal. The bond issue was a big success for the drugmaker, oversubscribed in all tranches.
- see the story at iStock Analyst
Related Articles:
AstraZeneca floats $6.9 billion in bonds
AstraZeneca snares MedImmune in $15.6B buyout
MedImmune CEO talks about AZ buyout
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: